- Home
- APGE
as 06-20-2025 10:30am EST
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.1B | IPO Year: | 2023 |
| Target Price: | $91.33 | AVG Volume (30 days): | 791.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.20 - $63.50 | Next Earning Date: | 08-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 743.14% |
Stock Insider Trading Activity of Apogee Therapeutics Inc. (APGE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dambkowski Carl | APGE | Chief Medical Officer | Jun 4 '25 | Sell | $36.96 | 2,725 | $100,716.00 | 241,723 | |
| Dambkowski Carl | APGE | Chief Medical Officer | May 7 '25 | Sell | $35.75 | 2,725 | $97,418.75 | 241,723 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Apr 2 '25 | Sell | $36.73 | 3,860 | $139,801.27 | 241,723 |
Latest Apogee Therapeutics Inc. News
APGE Breaking Stock News: Dive into APGE Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
GlobeNewswire
22 days ago
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
Zacks
a month ago
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
Benzinga
a month ago
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
MT Newswires
a month ago
Apogee Therapeutics Q1 Loss Widens
GlobeNewswire
a month ago
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
GlobeNewswire
a month ago
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
Zacks
2 months ago
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade
Compare APGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APGE Apogee Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.